Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics


Akero Therapeutics, Inc. (AKRO): $45.39

-1.41 (-3.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKRO Stock Price Chart Interactive Chart >

Price chart for AKRO

AKRO Price/Volume Stats

Current price $45.39 52-week high $54.88
Prev. close $46.80 52-week low $7.52
Day low $44.68 Volume 516,903
Day high $47.18 Avg. volume 597,612
50-day MA $46.53 Dividend yield N/A
200-day MA $26.61 Market Cap 2.12B

Akero Therapeutics, Inc. (AKRO) Company Bio


Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.


AKRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AKRO Latest Social Stream


Loading social stream, please wait...

View Full AKRO Social Stream

Latest AKRO News From Around the Web

Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. “Akero is thrilled to welcome Patrick to the team, especially following last year’s HARMONY study results, which further demonstrate EFX’s potential to treat

Yahoo | January 10, 2023

The Akero Therapeutics Inc. (AKRO) had a good session last reading, didn’t it?

The share price of Akero Therapeutics Inc. (NASDAQ:AKRO) fell to $44.49 per share on Wednesday from $49.49. While Akero Therapeutics Inc. has underperformed by -10.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKRO rose by 105.02%, with highs and lows ranging from $54.88 to $7.52, […]

US Post News | January 5, 2023

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.

GlobeNewswire | January 4, 2023

This Insider Just Sold Shares of Akero Therapeutics Inc

Related Stocks: AKRO ,

GuruFocus | December 30, 2022

Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program

Akero Therapeutics Inc (NASDAQ: AKRO) completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH) in patients with compensated cirrhosis fibrosis stage 4 (F4). Enrollment is also complete for the expansion cohort, known as Cohort D, evaluating EFX in combination with GLP-1 therapy in patients with fibrosis stage 1-3 (F1-F3) and Type 2 Diabetes. One hundred eighty-two patients have been randomized to receive once-weekly subcutane

Yahoo | December 22, 2022

Read More 'AKRO' Stories Here

AKRO Price Returns

1-mo 1.27%
3-mo 17.90%
6-mo 258.81%
1-year 141.31%
3-year 73.97%
5-year N/A
YTD -17.17%
2022 159.10%
2021 -18.02%
2020 16.24%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6463 seconds.